Nanomedicine to overcome radioresistance in glioblastoma stem-like cells and surviving clones

Trends in Pharmacological Sciences

Volumn 36, Issue 4, 2015, Pages 236-252

  Séhédic, Delphine ^a,b   Cikankowitz, Annabelle ^a,b   Hindré, François ^a,b   Davodeau, François ^b,c   Garcion, Emmanuel ^a,b  

^a UNIVERSITÉ D'ANGERS   (France)

^b Laboratoire d'Acoustique Environnementale   (France)

^c Team 12   (France)

Author keywords

glioblastoma; nanomedicine; radioresistance; radiosensitization; targeted therapies

Indexed keywords

ANIMAL; BRAIN NEOPLASMS; CANCER STEM CELL; CELL CLONE; GENETICS; GLIOBLASTOMA; HUMAN; NANOMEDICINE; PROCEDURES; RADIATION RESPONSE; SIGNAL TRANSDUCTION; TRENDS;

ANIMALS; BRAIN NEOPLASMS; CLONE CELLS; GLIOBLASTOMA; HUMANS; NANOMEDICINE; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION;

EID: 84939935260     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2015.02.002     Document Type: Review

References (212)

1. P. Kleihues The new WHO classification of brain-tumors Brain Pathol. 3 1993 255 268
2. R. Stupp Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N. Engl. J. Med. 352 2005 987 996
3. Z. Somosy Radiation response of cell organelles Micron 31 2000 165 181
4. 2 production under ionizing radiation Water 3 2011 235 253
5. D.T. Goodhead Initial events in the cellular effects of ionizing-radiations - clustered damage in DNA Int. J. Radiat. Biol. 65 1994 7 17
6. Y.C. Lim A role for homologous recombination and abnormal cell-cycle progression in radioresistance of glioma-initiating cells Mol. Cancer Ther. 11 2012 1863 1872
7. S.D. Bao Glioma stem cells promote radioresistance by preferential activation of the DNA damage response Nature 444 2006 756 760
8. S. Bao Targeting cancer stem cells through L1CAM suppresses glioma growth Cancer Res. 68 2008 6043 6048
9. D.W. Andrews A review of 3 current radiosurgery systems Surg. Neurol. 66 2006 559 564
10. B.A. Jereczek-Fossa Particle beam radiotherapy for head and neck tumors: Radiobiological basis and clinical experience Head Neck 28 2006 750 760
11. 188Re-lipid nanocapsules Biomaterials 32 2011 6781 6790
12. S.B. Schwarz Iodine-125 brachytherapy for brain tumours - a review Radiat. Oncol. 7 2012 30
13. A. Etcheverry DGKI methylation status modulates the prognostic value of MGMT in glioblastoma patients treated with combined radio-chemotherapy with temozolomide PLoS ONE 9 2014 e104455
14. L. Karayan-Tapon Predictive value of MGMT in glioblastoma: a multicenter study J. Clin. Oncol. 26 Suppl. 15S 2008 22065
15. M. Eoli Methylation of O-6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival Clin. Cancer Res. 13 2007 2606 2613
16. M.E. Hegi MGMT gene silencing and benefit from temozolomide in glioblastoma N. Engl. J. Med. 352 2005 997 1003
17. M. Weller MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat. Rev. Neurol. 6 2010 39 51
18. A.L. Rivera MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma Neuro Oncol. 12 2010 116 121
19. J. Chang Transferrin adsorption onto PLGA nanoparticles governs their interaction with biological systems from blood circulation to brain cancer cells Pharm. Res. 29 2011 1495 1505
20. S.K. Singh Identification of a cancer stem cell in human brain tumors Cancer Res. 63 2003 5821 5828
21. S.K. Singh Identification of human brain tumour initiating cells Nature 432 2004 396 401
22. L. Cheng Potential therapeutic implications of cancer stem cells in glioblastoma Biochem. Pharmacol. 80 2010 654 665
23. J. Lee Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines Cancer Cell 9 2006 391 403
24. J.M. Adams, and A. Strasser Is tumor growth sustained by rare cancer stem cells or dominant clones? Cancer Res. 68 2008 4018 4021
25. J. Wang Notch promotes radioresistance of glioma stem cells Stem Cells 28 2009 17 28
26. M.J. Walters Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats Br. J. Cancer 110 2014 1179 1188
27. Y. Wei Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells Proc. Natl. Acad. Sci. U.S.A. 110 2013 6829 6834
28. E. Bourseau-Guilmain The importance of the stem cell marker prominin-1/CD133 in the uptake of transferrin and in iron metabolism in human colon cancer Caco-2 cells PLoS ONE 6 2011 e25515
29. J.D. Lathia Integrin alpha 6 regulates glioblastoma stem cells Cell Stem Cell 6 2010 421 432
30. J.D. Lathia High-throughput flow cytometry screening reveals a role for junctional adhesion molecule a as a cancer stem cell maintenance factor Cell Rep. 6 2014 117 129
31. A. Schulte A distinct subset of glioma cell lines with stem cell-like properties reflects the transcriptional phenotype of glioblastomas and overexpresses CXCR4 as therapeutic target Glia 59 2011 590 602
32. - tumor-initiating cells in adult human gliomas Neurosurgery 62 2008 505 514
33. A. Tchoghandjian A2B5 cells from human glioblastoma have cancer stem cell properties Brain Pathol. 20 2010 211 221
34. R.G.W. Verhaak Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 Cancer Cell 17 2010 98 110
35. R. Morrison Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis J. Oncol. 2011 2011 941876
36. K. Yan The evolving landscape of glioblastoma stem cells Curr. Opin. Neurol. 26 2013 701 707
37. M. Santoni Essential role of Gli proteins in glioblastoma multiforme Curr. Protein Pept. Sci. 14 2013 133 140
38. D.G. Duda CXCL12 (SDF1 alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin. Cancer Res. 17 2011 2074 2080
39. D.A. Reardon Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme J. Clin. Oncol. 26 2008 5610 5617
40. P.H. Gutin Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation recurrent malignant gliomas Int. J. Radiat. Oncol. Biol. Phys. 75 2009 156 163
41. R.H. Bobo Convection-enhanced delivery of macromolecules in the brain Proc. Natl. Acad. Sci. U.S.A. 91 1994 2076 2080
42. S. Petit Local chemotherapy of malignant glioma: from syringe injections to nanotechnology Revue Neurol. (Paris) 164 2008 547 553
43. A. Jain Guiding intracortical brain tumour cells to an extracortical cytotoxic hydrogel using aligned polymeric nanofibres Nat. Mater. 13 2014 309 316
44. M.R. Zalutsky Clinical experience with alpha-particle-emitting At-211: Treatment of recurrent brain tumor patients with At-211-labeled chimeric antitenascin monoclonal antibody 81C6 J. Nucl. Med. 49 2008 30 38
45. A.E. Nel Understanding biophysicochemical interactions at the nano-bio interface Nat. Mater. 8 2009 543 557
46. D. Peer Nanocarriers as an emerging platform for cancer therapy Nat. Nanotechnol. 2 2007 751 760
47. M.C. Thompson Genornics identifies medulloblastoma subgroups that are enriched for specific genetic alterations J. Clin. Oncol. 24 2006 1924 1931
48. T. Chiba Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation Gastroenterology 133 2007 937 950
49. Y. Kim Wnt activation is implicated in glioblastoma radioresistance Lab. Invest. 92 2012 466 473
50. T. Ashizawa Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma Int. J. Oncol. 43 2013 219 227
51. T.M. Thornton Phosphorylation by p38 MAPK as an alternative pathway for GSK3 beta inactivation Science 320 2008 667 670
52. E.T. Strovel Protein phosphatase 2C alpha dephosphorylates axin and activates LEF-1-dependent transcription J. Biol. Chem. 275 2000 2399 2403
53. W. Luo Protein phosphatase 1 regulates assembly and function of the beta-catenin degradation complex EMBO J. 26 2007 1511 1521
54. S. Smith Tankyrase, a poly(ADP-ribose) polymerase at human telomeres Science 282 1998 1484 1487
55. S.J. Hsiao, and S. Smith Tankyrase function at telomeres, spindle poles, and beyond Biochimie 90 2008 83 92
56. B.Z. Chen Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer Nat. Chem. Biol. 5 2009 100 107
57. J. Waaler Novel synthetic antagonists of canonical wnt signaling inhibit colorectal cancer cell growth Cancer Res. 71 2011 197 205
58. J. Waaler A novel tankyrase inhibitor decreases canonical wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice Cancer Res. 72 2012 2822 2832
59. S.M.A. Huang Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling Nature 461 2009 614 620
60. T. Karlberg Structural basis for the Interaction between tankyrase-2 and a potent Wnt-signaling Inhibitor J. Med. Chem. 53 2010 5352 5355
61. E. Wahlberg Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors Nat. Biotechnol. 30 2012 283 288
62. M.Y. Chen The anti-kelminthic niclosamide inhibits Wnt/Frizzled1 signaling Biochemistry 48 2009 10267 10274
63. W.Y. Lu Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/beta-catenin pathway PLoS ONE 6 2011 e29290
64. J.X. Pan Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells Chin. J. Cancer 31 2012 178 184
65. T. Osada Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC Mutations Cancer Res. 71 2011 4172 4182
66. Y.H. Li Dkk1 stabilizes Wnt co-receptor LRP6: implication for Wnt ligand-induced LRP6 down-regulation PLoS ONE 5 2010 e11014
67. L. Zhou Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the beta-catenin signaling activity Cancer Lett. 193 2003 161 170
68. A.B. Heimberger Mechanisms of action of rapamycin in gliomas Neuro Oncol. 7 2005 1 11
69. R.C. Castellino, and D.L. Durden Mechanisms of disease: the PI3K-Akt-PTEN signaling node - an intercept point for the control of angiogenesis in brain tumors Nat. Clin. Pract. Neurol. 3 2007 682 693
70. B.H. Jiang, and L.Z. Liu PI3K/PTEN signaling in angiogenesis and tumorigenesis G.F.V. Woude, G. Klein, Advances in Cancer Research Vol. 102 2009 Academic Press 19 65
71. C.B. Knobbe Genetic alteration and expression of the phosphoinositol-3-kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas Neuropathol. Appl. Neurobiol. 31 2005 486 490
72. Y. Sonoda Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma Cancer Res. 61 2001 6674 6678
73. E. Chautard Role of Akt in human malignant glioma: from oncogenesis to tumor aggressiveness J. Neurooncol. 117 2014 205 215
74. A. Anandharaj Rapamycin-mediated mTOR inhibition attenuates survivin and sensitizes glioblastoma cells to radiation therapy Acta Biochim. Biophys. Sin. (Shanghai) 43 2011 292 300
75. E.T. Shinohara Enhanced radiation damage of tumor vasculature by mTOR inhibitors Oncogene 24 2005 5414 5422
76. J.S. Eshleman Inhibition of the mammalian target of rapamycin sensitizes U87 Xenografts to fractionated radiation therapy Cancer Res. 62 2002 7291 7297
77. J.S. Hardwick Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins Proc. Natl. Acad. Sci. U.S.A. 96 1999 14866 14870
78. M. Guba Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor Nat. Med. 8 2002 128 135
79. O.L. Chinot Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma N. Engl. J. Med. 370 2014 709 722
80. D. Hambardzumyan PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo Genes Dev. 22 2008 436 448
81. K.E. O'Reilly mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Cancer Res. 66 2006 1500 1508
82. D.D. Sarbassov Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 307 2005 1098 1101
83. F. Tremblay Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance Proc. Natl. Acad. Sci. U.S.A. 104 2007 14056 14061
84. S. Osuka IGF1 receptor signaling regulates adaptive radioprotection in glioma stem cells Stem Cells 31 2013 627 640
85. P.D. Brown Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177 J. Clin. Oncol. 26 2008 5603 5609
86. M.D. Prados Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma J. Clin. Oncol. 27 2009 579 584
87. D.M. Peereboom Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme J. Neuro Oncol. 98 2010 93 99
88. S.E. Combs Influence of EGFR-amplification, EGFR-, EGFRvIII- and PTEN-expression as well as MGMT-promotor methylation status on outcome in patients with primary glioblastoma treated with radiation, temozolomide and EGFR-inhibition with Cetuximab: interim analysis from the GERT-protocol Strahlenther. Und Onkol. 185 2009 16
89. J. Hainsworth Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma Clin. Adv. Hematol. Oncol. 10 2012 240 246
90. D.A. Reardon Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma J. Neuro Oncol. 96 2010 219 230
91. T.N. Kreisl A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM) J. Neuro Oncol. 92 2009 99 105
92. M. Hayakawa Synthesis and biological evaluation of pyrido 3′,2′: 4,5 furo 3,2-d pyrimidine derivatives as novel PI3 kinase p110 alpha inhibitors Bioorg. Med. Chem. Lett. 17 2007 2438 2442
93. S-M. Maira Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity Mol. Cancer Ther. 7 2008 1851 1863
94. Q.W. Fan Akt and autophagy cooperate to promote survival of drug-resistant glioma Sci. Signal. 3 2010 ra81
95. B. Mukherjee The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses Neoplasia 14 2012 34 43
96. G.J. Cerniglia Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 Mol. Pharmacol. 82 2012 1230 1240
97. O.J. Becher Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma Cancer Res. 70 2010 2548 2557
98. E. Chautard Akt signaling pathway: a target for radiosensitizing human malignant glioma Neuro Oncol. 12 2010 434 443
99. B.W. Purow Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation Cancer Res. 65 2005 2353 2363
100. X. Fan Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors Cancer Res. 66 2006 7445 7452
101. J.L. Wang Notch promotes radioresistance of glioma stem cells Stem Cells 28 2010 17 28
102. + tumor cells Arch. Med. Res. 41 2010 519 529
103. L.R. Perumalsamy A hierarchical cascade activated by non-canonical Notch signaling and the mTOR-Rictor complex regulates neglect-induced death in mammalian cells Cell Death Differ. 16 2009 879 889
104. J. Wu Arsenic trioxide depletes cancer stem-like cells and inhibits repopulation of neurosphere derived from glioblastoma by downregulation of Notch pathway Toxicol. Lett. 220 2013 61 69
105. V. Clement HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity Curr. Biol. 17 2007 165 172
106. T. Takezaki Essential role of the Hedgehog signaling pathway in human glioma-initiating cells Cancer Sci. 102 2011 1306 1312
107. E.E. Bar Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma Stem Cells 25 2007 2524 2533
108. P. Hau TGF-beta 2 signaling in high-grade gliomas Curr. Pharmaceutical Biotechnol. 12 2011 2150 2157
109. E. Satoh Effect of irradiation on transforming growth factor-beta secretion by malignant glioma cells J. Neuro Oncol. 33 1997 195 200
110. J.R. Wang Cellular sources of transforming growth factor-beta isoforms in early and chronic radiation enteropathy Am. J. Pathol. 153 1998 1531 1540
111. M.H. Barcellos-Hoff Therapeutic targets in malignant glioblastoma microenvironment Semin. Radiat. Oncol. 19 2009 163 170
112. M.E. Jobling Isoform-specific activation of latent transforming growth factor beta (LTGF-beta) by reactive oxygen species Radiat. Res. 166 2006 839 848
113. C. Shao Role of TGF-beta 1 and nitric oxide in the bystander response of irradiated glioma cells Oncogene 27 2008 434 440
114. M. Zhang Blockade of TGF-beta signaling by the TGF beta R-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma Cancer Res. 71 2011 7155 7167
115. M.X. Zhang Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-beta receptor I kinase Inhibitor LY2109761 Neoplasia 13 2011 537 549
116. M.E. Hardee Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-beta Cancer Res. 72 2012 4119 4129
117. P. Hau Inhibition of TGF-beta 2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies Oligonucleotides 17 2007 201 212
118. U. Bogdahn Targeted therapy for high-grade glioma with the TGF-beta 2 inhibitor trabedersen: results of a randomized and controlled phase IIb study Neuro Oncol. 13 2011 132 142
119. N. de la Iglesia STAT3 regulation of glioblastoma pathogenesis Curr. Mol. Med. 9 2009 580 590
120. C.J. Chang Inhibition of phosphorylated STAT3 by cucurbitacin I enhances chemoradiosensitivity in medulloblastoma-derived cancer stem cells Childs Nerv. Syst. 28 2012 363 373
121. Y.P. Yang Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis J. Cell. Physiol. 227 2012 976 993
122. E. Cohen-Jonathan Moyal From bench to bedside: experience of the glioblastoma model for the optimization of radiosensitization Cancer Radiother. 16 2012 25 28
123. E. Cohen-Jonathan Radioresistance induced by the high molecular forms of the basic fibroblast growth factor is associated with an increased G2 delay and a hyperphosphorylation of p34CDC2 in HeLa cells Cancer Res. 57 1997 1364 1370
124. I. Ader The radioprotective effect of the 24 kDa FGF-2 isoform in HeLa cells is related to an increased expression and activity of the DNA dependent protein kinase (DNA-PK) catalytic subunit Oncogene 21 2002 6471 6479
125. I. Ader RhoB controls the 24 kDa FGF-2-induced radioresistance in HeLa cells by preventing post-mitotic cell death Oncogene 21 2002 5998 6006
126. K. Dittmann Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase J. Biol. Chem. 280 2005 31182 31189
127. N. Skuli Activation of RhoB by hypoxia controls hypoxia-inducible factor-1 alpha stabilization through glycogen synthase kinase-3 in U87 glioblastoma cells Cancer Res. 66 2006 482 489
128. J. Milia Farnesylated RhoB inhibits radiation-induced mitotic cell death and controls radiation-induced centrosome overduplication Cell Death Differ. 12 2005 492 501
129. C. Delmas Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation Int. J. Cancer 100 2002 43 48
130. C. Delmas The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft Clin. Cancer Res. 9 2003 6062 6068
131. I. Ader Inhibition of Rho pathways induces radiosensitization and oxygenation in human glioblastoma xenografts Oncogene 22 2003 8861 8869
132. A. Haimovitzfriedman Protein-kinase-C mediates basic fibroblast growth-factor protection of endothelial-cells against radiation-induced apoptosis Cancer Res. 54 1994 2591 2597
133. C. Wild-Bode Sublethal irradiation promotes migration and invasiveness of glioma cells: Implications for radiotherapy of human glioblastoma Cancer Res. 61 2001 2744 2750
134. S. Monferran Alpha v beta 3 and alpha v beta 5 integrins control glioma cell response to ionising radiation through ILK and RhoB Int. J. Cancer 123 2008 357 364
135. E.C.J. Moyal Phase I trial of tipifarnib (R115777) concurrent with radiotherapy in patients with glioblastoma multiforme Int. J. Radiat. Oncol. Biol. Phys. 68 2007 1396 1401
136. A. Ducassou Alpha v beta 3 Integrin and fibroblast growth factor receptor 1 (FGFR1): prognostic factors in a phase I-II clinical trial associating continuous administration of tipifarnib with radiotherapy for patients with newly diagnosed glioblastoma Eur. J. Cancer 49 2013 2161 2169
137. R. Stupp Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma J. Clin. Oncol. 28 2010 2712 2718
138. I. Ader Preclinical evidence that SSR 128129E - a novel small-molecule multi-fibroblast growth factor receptor blocker - radiosensitises human glioblastoma Eur. J. Cancer 50 2014 2351 2359
139. A.L. Harris Hypoxia - a key regulatory factor in tumour growth Nat. Rev. Cancer 2 2002 38 47
140. B. Keith, and M.C. Simon Hypoxia-inducible factors, stem cells, and cancer Cell 129 2007 465 472
141. Z. Li Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells Cancer Cell 15 2009 501 513
142. K.J. Williams Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1 Radiother. Oncol. 75 2005 89 98
143. R. Bernardi PML inhibits HIF-1 alpha translation and neoangiogenesis through repression of mTOR Nature 442 2006 779 785
144. D. Papahadjopoulos Sterically stabilized liposomes - improvements in pharmacokinetics and antitumor therapeutic efficacy Proc. Natl. Acad. Sci. U.S.A. 88 1991 11460 11464
145. D.D. Lasic Doxorubicin in sterically stabilized liposomes Nature 380 1996 561 562
146. N. Bertrand Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology Adv. Drug Deliv. Rev. 66 2014 2 25
147. R.K. Jain, and T. Stylianopoulos Delivering nanomedicine to solid tumors Nat. Rev. Clin. Oncol. 7 2010 653 664
148. R.S. Mello Radiation-dose enhancement in tumors with iodine Med. Phys. 10 1983 75 78
149. A. Norman X-ray phototherapy for canine brain masses Radiat. Oncol. Investig. 5 1997 8 14
150. J.H. Rose First radiotherapy of human metastatic brain tumors delivered by a computerized tomography scanner (CTRx) Int. J. Radiat. Oncol. Biol. Phys. 45 1999 1127 1132
151. J. Rousseau Intracerebral delivery of 5-iodo-2′-deoxyuridine in combination with synchrotron stereotactic radiation for the therapy of the F98 glioma J. Synchrotron Radiat. 16 2009 573 581
152. 125IUdR loaded biodegradable microspheres for controlled delivery to the brain J. Microencapsul. 15 1998 789 801
153. D. Kwatra Nanoparticles in radiation therapy: a summary of various approaches to enhance radiosensitization in cancer Transl. Cancer Res. 2 2013 330 342
154. Y. Zheng Radiosensitization of DNA by gold nanoparticles irradiated with high-energy electrons Radiat. Res. 169 2008 19 27
155. D.Y. Joh Selective targeting of brain tumors with gold nanoparticle-induced radiosensitization PLoS ONE 8 2013 e62425
156. L. Bobyk Photoactivation of gold nanoparticles for glioma treatment Nanomed. Nanotechnol. Biol. Med. 9 2013 1089 1097
157. P. Mowat In vitro radiosensitizing effects of ultrasmall gadolinium based particles on tumour cells J. Nanosci. Nanotechnol. 11 2011 7833 7839
158. S.E.A. Gratton The effect of particle design on cellular internalization pathways Proc. Natl. Acad. Sci. U.S.A. 105 2008 11613 11618
159. A.L. Papa Effect of reaction parameters on composition and morphology of titanate nanomaterials J. Phys. Chem. C 113 2009 12682 12689
160. C. Mirjolet The radiosensitization effect of titanate nanotubes as a new tool in radiation therapy for glioblastoma: a proof-of-concept Radiother. Oncol. 108 2013 136 142
161. E.J. Park Oxidative stress and apoptosis induced by titanium dioxide nanoparticles in cultured BEAS-2B cells Toxicol. Lett. 180 2008 222 229
162. Q. Saquib Titanium dioxide nanoparticles induced cytotoxicity, oxidative stress and DNA damage in human amnion epithelial (WISH) cells Toxicol. Vitro 26 2012 351 361
163. 2 nanofibers in HeLa cells Eur. J. Pharm. Biopharm. 81 2012 324 333
164. S.A. Krueger The effects of G2-phase enrichment and checkpoint abrogation on low-dose hyper-radiosensitivity Int. J. Radiat. Oncol. Biol. Phys. 77 2010 1509 1517
165. R. Xu Ag nanoparticles sensitize IR-induced killing of cancer cells Cell Res. 19 2009 1031 1034
166. J. Marill Hafnium oxide nanoparticles: toward an in vitro predictive biological effect? Radiat. Oncol. Investig. 9 2014 150
167. A. Paillard The importance of endo-lysosomal escape with lipid nanocapsules for drug subcellular bioavailability Biomaterials 31 2010 7542 7554
168. J. Glass Fractionated stereotactic radiotherapy with cis-platinum radiosensitization in the treatment of recurrent, progressive, or persistent malignant astrocytoma Am. J. Clin. Oncol. Cancer Clin. Trials 20 1997 226 229
169. G. Charest Concomitant treatment of F98 glioma cells with new liposomal platinum compounds and ionizing radiation J. Neuro Oncol. 97 2010 187 193
170. H.E. Shahmabadi Efficacy of cisplatin-loaded polybutyl cyanoacrylate nanoparticles on the glioblastoma Tumor Biol. 35 2014 4799 4806
171. P.B. Chastagner Comparison of doxorubicin and its non-pegylated liposomal form as radiosensitizer in high grade glioma xenografts J. Clin. Oncol. 23 Suppl. 16S 2005 1524
172. C.P. Beier RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma - a phase II study BMC Cancer 9 2009 308
173. Y.P. Hu On the mechanism of action of doxorubicin encapsulation in nanospheres for the reversal of multidrug resistance Cancer Chemother. Pharmacol. 37 1996 556 560
174. K. Tahara Intracellular drug delivery using polysorbate 80-modified poly(D,L-lactide-co-glycolide) nanospheres to glioblastoma cells J. Microencapsul. 28 2011 29 36
175. M. Zucchetti Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin Cancer Chemother. Pharmacol. 44 1999 173 176
176. E. Garcion A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats Mol. Cancer Ther. 5 2006 1710 1722
177. S. Vinchon-Petit In vivo evaluation of intracellular drug-nanocarriers infused into intracranial tumours by convection-enhanced delivery: distribution and radiosensitisation efficacy J. Neuro Oncol. 97 2010 195 205
178. C. Jin Radiosensitization of paclitaxel, etanidazole and paclitaxel plus etanidazole nanoparticles on hypoxic human tumor cells in vitro Biomaterials 28 2007 3724 3730
179. P. Gabikian Radiosensitization of malignant gliomas following intracranial delivery of paclitaxel biodegradable polymer microspheres J. Neurosurg. 120 2014 1078 1085
180. G.Z. Gu The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells Biomaterials 34 2013 5138 5148
181. X.Y. Jiang PEGylated poly(trimethylene carbonate) nanoparticles loaded with paclitaxel for the treatment of advanced glioma: in vitro and in vivo evaluation Int. J. Pharm. 420 2011 385 394
182. H. Brem Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas Lancet 345 1995 1008 1012
183. M. Westphal A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma Neuro Oncol. 5 2003 79 88
184. P. Menei Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma - a pilot study Cancer 86 1999 325 330
185. P. Menei Stereotaxic implantation of 5-fluorouracil-releasing microspheres in malignant glioma - a phase I study Cancer 100 2004 405 410
186. P. Menei Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: a randomized phase II trial Neurosurgery 56 2005 242 247
187. S. Gaca Targeting by cmHsp70.1-antibody coated and survivin miRNA plasmid loaded nanoparticles to radiosensitize glioblastoma cells J. Control. Release 172 2013 201 206
188. Y. Ping Inhibition of the EGFR with nanoparticles encapsulating antisense oligonucleotides of the EGFR enhances radiosensitivity in SCCVII cells Med. Oncol. 27 2010 715 721
189. A. Griveau Silencing of miR-21 by locked nucleic acid-lipid nanocapsule complexes sensitize human glioblastoma cells to radiation-induced cell death Int. J. Pharm. 454 2013 765 774
190. E. Ruoslahti Specialization of tumour vasculature Nat. Rev. Cancer 2 2002 83 90
191. E. Ruoslahti, and M.D. Pierschbacher Arg-Gly-Asp - a versatile cell recognition signal Cell 44 1986 517 518
192. Z. Liu In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice Nat. Nanotechnol. 2 2007 47 52
193. C.F. Zhang Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner Cancer Res. 67 2007 1555 1562
194. X.M. Qian In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags Nat. Biotechnol. 26 2008 83 90
195. S. Yang Biomimetic, synthetic HDL nanostructures for lymphoma Proc. Natl. Acad. Sci. U.S.A. 110 2013 2511 2516
196. R. Marega Antibody-functionalized polymer-coated gold nanoparticles targeting cancer cells: an in vitro and in vivo study J. Mater. Chem. 22 2012 21305 21312
197. L. Karmani Zr-89-labeled anti-endoglin antibody-targeted gold nanoparticles for imaging cancer: implications for future cancer therapy Nanomedicine 9 2014 1923 1937
198. 89Zr-labeled cetuximab in mice Contrast Media Mol. Imaging 8 2013 402 408
199. T.A. Read Local endostatin treatment of gliomas administered by microencapsulated producer cells Nat. Biotechnol. 19 2001 29 34
200. A. Kumar Curcumin-loaded lipid nanocarrier for improving biovaibility, stability and cytotoxicity against malignant glioma cells Drug Deliv. 2014 Published online May 14, 2014. http://dx.doi.org/10.3109/10717544.2014.909906
201. M.T. Mirgani Dendrosomal curcumin nanoformulation downregulates pluripotency genes via miR-145 activation in U87MG glioblastoma cells Int. J. Nanomed. 9 2014 403 417
202. F. Dilnawaz, and S.K. Sahoo Enhanced accumulation of curcumin and temozolomide loaded magnetic nanoparticles executes profound cytotoxic effect in glioblastoma spheroid model Eur. J. Pharm. Biopharm. 85 2013 452 462
203. K.J. Lim A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors Cancer Biol. Ther. 11 2011 464 473
204. E.A. Appel Enhanced stability and activity of temozolomide in primary glioblastoma multiforme cells with cucurbit[n]uril Chem. Commun. (Camb.) 48 2012 9843 9845
205. J.S. Gill Effects of NF kappa B decoy oligonucleotides released from biodegradable polymer microparticles on a glioblastoma cell line Biomaterials 23 2002 2773 2781
206. Y. Chen Schedule-dependent pulsed paclitaxel radiosensitization for thoracic malignancy Am. J. Clin. Oncol. Cancer Clin. Trials 24 2001 432 437
207. E. Ojima The optimal schedule for 5-fluorouracil radiosensitization in colon cancer cell lines Oncol. Rep. 16 2006 1085 1091
208. S. Sofou Radionuclide carriers for targeting of cancer Int. J. Nanomed. 3 2008 181 199
209. M. Vitucci Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis Neuro Oncol. 15 2013 1317 1329
210. A. Carracedo Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer J. Clin. Invest. 118 2008 3065 3074
211. I. Paul Current understanding on EGFR and Wnt/β-catenin signaling in glioma and their possible crosstalk Genes Cancer 4 2013 427 446
212. S.K. Roy Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer J. Mol. Signal. 5 2010 10